Adrenogenital Syndrome Treatment Global Market Report 2025

The adrenogenital syndrome treatment market size has grown strongly in recent years. It will grow from $12.08 billion in 2024 to $12.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historical period can be attributed to greater awareness of rare diseases, a rising pediatric population, increased clinical awareness and education, a higher incidence of hormonal disorders, and improved access to healthcare services.

The adrenogenital syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $16.19 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth during the forecast period can be driven by advancements in genetic research, a growing patient population, increased adoption of targeted therapies, expanding healthcare infrastructure in emerging markets, and greater government funding for rare disease treatments. Key trends in this period include the rise of personalized medicine, the adoption of gene therapy applications, the integration of digital health tools, the development of non-invasive diagnostic techniques, and collaborations between pharmaceutical companies and research institutions.

The increasing adoption of personalized medicine is expected to drive the expansion of the adrenogenital syndrome treatment market. Personalized medicine involves tailoring treatments to an individual’s genetic profile, lifestyle, and specific health needs to enhance efficacy and safety. The growing preference for personalized medicine is driven by advancements in genetics, rising patient demand for customized treatments, and improvements in healthcare technologies. In the context of adrenogenital syndrome, personalized treatments are designed based on a patient’s unique genetic makeup and hormone levels, optimizing therapeutic outcomes while minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that FDA approvals for personalized treatments increased to 16 in 2023, including seven for cancer and three for other conditions, up from six in 2022. As a result, the rising adoption of personalized medicine is expected to contribute to the growth of the adrenogenital syndrome treatment market.

Leading companies in the adrenogenital syndrome treatment market are focusing on developing advanced therapies, such as innovative orphan drugs, to address unmet medical needs, improve patient outcomes, and expand their market presence by offering targeted solutions for rare and complex disorders. Orphan drugs are specialized medications developed for rare and often severe diseases that have limited or no existing treatment options. For instance, in December 2024, Neurocrine Biosciences, a US-based biotech company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) for CRENESSITY (crinecerfont), a novel treatment for children and adults with classic Congenital Adrenal Hyperplasia (CAH), a form of adrenogenital syndrome. This approval marks a significant breakthrough, introducing the first new therapeutic option for CAH in seventy years and addressing a critical gap in treating this rare endocrine disorder.

In November 2022, Neurocrine Biosciences, Inc., a US-based biotech company, acquired Diurnal Group plc for $58.03 million. This acquisition aims to strengthen Neurocrine Biosciences' portfolio in rare endocrine diseases and enhance its global market position in the treatment of hormonal disorders. Diurnal Group plc, a UK-based biotech company, specializes in developing therapies for chronic endocrine conditions, including adrenogenital syndrome.

Major players in the adrenogenital syndrome treatment market are Pfizer Inc., Thermo Fisher Scientific, Novartis AG, Teva Pharmaceutical Industries Ltd., Lundbeck A/S, Neurocrine Biosciences Inc., Sandoz Group AG, IP Group Plc, BridgeBio Pharma, Bristol Laboratories Ltd, Changi General Hospital Pte Ltd, OMass Therapeutics, Spruce Biosciences Inc., Axplora, Diurnal Ltd., Alder Biopharmaceuticals Inc, Adrenas Therapeutics Inc, Crinetics Pharmaceuticals Inc., EffRx Pharmaceuticals, and Millendo Therapeutics Inc.

North America was the largest region in the adrenogenital syndrome treatment market in 2024. The regions covered in adrenogenital syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adrenogenital syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adrenogenital syndrome is a genetic disorder that affects the adrenal glands, causing an imbalance in hormone production, particularly cortisol and aldosterone. Treatment aims to restore hormonal balance through corticosteroids to manage symptoms and prevent complications such as adrenal crises and abnormal growth patterns.

The primary drug types for treating adrenogenital syndrome include mineralocorticoids and glucocorticoids. Mineralocorticoids are a class of steroid hormones that regulate mineral balance, particularly sodium and potassium, with aldosterone being the most well-known example. These drugs are administered via various routes, including oral, parenteral, intravenous, and inhalation methods, and utilize key technologies such as genetic testing, hormone replacement therapies, and surgical procedures. They are distributed through hospital and retail pharmacies, among others, and are used in hospitals, clinics, and home care settings.

The adrenogenital syndrome treatment market research report is one of a series of new reports that provides adrenogenital syndrome treatment market statistics, including the adrenogenital syndrome treatment industry global market size, regional shares, competitors with the adrenogenital syndrome treatment market share, detailed adrenogenital syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenogenital syndrome treatment industry. This adrenogenital syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adrenogenital syndrome treatment market consists of revenues earned by entities by providing services such as therapy services, psychological and psychosocial support services, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenogenital syndrome treatment market also includes sales of androgen modulators, dietary and nutritional supplements, and diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.